Adjuvant Therapy In Cancer Treatment Research Articles

Postbiotics as Adjuvant Therapy in Cancer Care

Postbiotics are defined as a preparation of inanimate microorganisms and/or their components that confers a health benefit to the host. They range from cell wall fragments to metabolites, bacterial lysates, extracellular vesicles, and short-chain fatty acids (SCFAs). Postbiotics may influence carcinogenesis via a variety of mechanisms. They can promote homeostatic immune responses, reduce inflammation, induce selective cytotoxicity against tumor cells, as well as the enabling the control of tumor cell proliferation and enhancing intestinal epithelial barrier function. Therefore, probiotics can serve as an adjunct strategy in anticancer treatment together with chemotherapy and immunotherapy. Up to now, the only relevant postbiotics used as interventions in oncological patients remain vitamin K molecules, with few phase-II and III trials available. In fact, postbiotics’ levels are strictly dependent on the gut microbiota’s composition, which may vary between individuals and can be altered under different physiological and pathological conditions. Therefore, the lack of consistent clinical evidence supporting postbiotics’ efficacy is due to their poor bioavailability, short half-life, and fluctuating levels. Synbiotics, a mixture of prebiotics and probiotics, are expected to have a more homogeneous bioavailability with respect to postbiotics and may have greater potential for future development. In this review, we focus on the role of postbiotics as an adjuvant therapy in cancer treatment.

A COMPREHENSIVE REVIEW ON PHARMACOLOGICAL POTENTIALS OF CAFFEINE

Caffeine is a naturally occurring methylxanthine compound found in various plants, such as coffee beans, tea leaves, and cocoa beans. It is widely consumed worldwide in the form of beverages, dietary supplements, and medications. Caffeine exerts its pharmacological effects primarily through its interaction with adenosine receptors, resulting in widespread physiological and neurological changes. In the field of medicinal chemistry, caffeine has been extensively studied due to its diverse pharmacological actions and potential therapeutic applications. This abstract highlights the key pharmacological actions of caffeine and its relevance in medicinal chemistry research. Caffeine acts as a non-selective antagonist of adenosine receptors, particularly the A1 and A2A subtypes. By inhibiting adenosine binding, caffeine prevents the activation of these receptors, leading to increased neural activity and the release of neurotransmitters such as dopamine and glutamate. This mechanism of action underlies caffeine’s stimulant effects, including increased alertness, reduced fatigue, and improved cognitive function. Caffeine exhibits broncho dilatory effects by acting as a phosphodiesterase inhibitor, primarily targeting phosphodiesterase type 4 (PDE4). Inhibition of PDE4 prevents the breakdown of cyclic adenosine monophosphate (cAMP), leading to smooth muscle relaxation and bronchodilation. This property of caffeine has been utilized in the treatment of asthma and chronic obstructive pulmonary disease (COPD). Furthermore, caffeine possesses diuretic properties by inhibiting the reabsorption of sodium in the renal tubules. This leads to increased water excretion and urine production. The diuretic effects of caffeine have found applications in the management of fluid overload conditions, such as edema and heart failure. Additionally, caffeine has been investigated for its potential anticancer properties. Several studies have shown that caffeine can enhance the cytotoxic effects of certain chemotherapeutic agents, inhibit DNA repair mechanisms, and induce apoptosis in cancer cells. These findings have sparked interest in caffeine as an adjuvant therapy for cancer treatment, although further research is needed to establish its clinical efficacy and safety. In conclusion, caffeine exhibits a wide range of pharmacological actions, making it a versatile compound in medicinal chemistry research. Its interactions with adenosine receptors, phosphodiesterase, and renal tubules contribute to its stimulant, broncho dilatory, diuretic, and potentially anticancer effects. The understanding of caffeine’s pharmacological actions provides valuable insights for the development of novel drugs and therapeutic approaches in various fields of medicine.

Green HPLC Method for Simultaneous Analysis of Three Natural Antioxidants by Analytical Quality by Design.

Glutathione, silybin, and curcumin are well-known potential antioxidants that are recommended as adjuvant therapy in cancer treatment. Based on the principles of Analytical Quality by Design (AQbD) and green analytical chemistry, a simple, robust, and environmentally benign HPLC method for the simultaneous estimation of glutathione, silybin, and curcumin in bulk and formulation was performed. Elution was achieved by an Agilent Eclipse XDB C18 (150 mm × 4.6 mm id, 3.5 μm) column using a gradient mobile phase composed of ethanol-water pH 6.7 (with 0.1%, v/v orthophosphoric acid) and 1.07 mL/min flow rate with PDA detection at 215 nm. Critical method variables were identified by risk assessment using an Ishikawa diagram, and multivariate optimization of the experimental conditions for the HPLC technique was accomplished by central composite design using design of experiments (DoE) software. The separation was achieved within 15 min, where the retention time of glutathione, silybin, and curcumin were 3.3, 4.9, and 7.3 min, respectively. The standard curve was linear in the range of 3.75-26.25 µg/mL for glutathione, 62.50-437.50 µg/mL for silybin, and 12.5-87.50 µg/mL for curcumin. The developed method was validated as per ICH guidelines Q2 (R1), and all the parameters are within specified limits. The proposed method is simple, precise, and robust, which can be employed for routine analysis and also concluded to be a greener approach according to AGREE, Green Analytical Procedure Index, and analytical eco-scale tools. The chosen antioxidants were evaluated for the very first time simultaneously using the chromatographic technique in bulk and dosage forms employing green solvents. The peak purity of all three compounds was studied using a PDA detector. Wastage was reduced in terms of time, cost, and solvents by employing AQbD elements and tools. Complete application of environmentally sustainable safe solvents were employed.

Effects of Active Video Games in Patients With Cancer: Systematic Review.

Physical activity (PA) is now considered an adjuvant therapy in cancer treatment; nevertheless, multiple barriers could reduce PA engagement during treatment. Active video games (AVGs) lead to the achievement of mild- to moderate-intensity PA and represent a promising tool for regular movement and exercise. This paper aims to review the current literature and provide updated content on the physiological and psychological effects of AVG-based interventions in patients with cancer undergoing treatment. Four electronic databases were investigated. Studies reporting on AVG interventions delivered to patients undergoing treatment were included. A total of 21 articles (17 interventions) were identified for data extraction and quality assessment. A total of 362 patients with cancer participated in the studies (number of participants 3-70). The majority underwent treatment for breast, lung, prostate, hematologic, or oral or laryngeal cancer. The types and stages of cancer varied in all studies. Participants ranged in age from 3 to 93 years. Four studies included patients with pediatric cancer. The duration of interventions ranged from 2 to 16 weeks, with a minimum of 2 sessions per week and a maximum of 1 daily session. Sessions were supervised in 10 studies, and 7 included home-based interventions. AVG interventions improved endurance, quality of life, cancer-related fatigue, and self-efficacy. Effects were mixed on strength, physical function, and depression. AVGs did not affect activity level, body composition, or anxiety. Compared with standard physiotherapy, physiological effects were lower or similar, and psychological effects were higher or similar. Overall, our results suggest that AVGs can be recommended to patients undergoing cancer treatment, given the physiological and psychological benefits. When AVGs are proposed, supervision of the sessions should be considered as it can limit dropouts. In the future, it is important to develop AVGs that combine endurance and muscle strengthening, with the possibility of achieving moderate to high exercise intensity, depending on the physical abilities of the patients, as indicated in the World Health Organization's recommendations.

Tabakkonsum und Behandlung von Tabakabhängigkeit

Jedes Jahr sterben in Deutschland rund 127.000 Menschen an den Folgen des Rauchens. Darunter befinden sich 85.000 Menschen mit einer tabakassoziierten Krebserkrankung. Dennoch raucht in Deutschland immer noch etwa ein Viertel der erwachsenen Bevölkerung, oftmals auch dann noch, wenn eine tabakassoziierte Erkrankung auftritt. Viele Rauchende schaffen die Abstinenz nicht ohne Unterstützung. Dieser Beitrag gibt einen Überblick über wirksame Strategien zur Tabakentwöhnung und beschreibt das Potenzial der Tabakentwöhnung im Rahmen der adjuvanten Therapie bei Tumorerkrankungen. Darüber hinaus werden gesundheitspolitische Herausforderungen im Rahmen der Versorgung zur Tabakentwöhnung aufgezeigt. Eine Vielzahl von psychologischen und pharmakologischen Interventionsmethoden zur Tabakentwöhnung ist wirksam. Rauchenden Patienten und Patientinnen mit tabakassoziierten Erkrankungen soll eine Tabakentwöhnungstherapie angeboten werden. Tabakentwöhnung ist als adjuvante Therapie bei Tumorerkrankungen von großer Bedeutung. Sie verursacht vergleichsweise geringe Kosten und bringt erhebliche Vorteile für die Krankheitsgenesung und Lebensqualität der Betroffenen. Allerdings wird sie in Deutschland nur als wenig regulierte Präventionsmaßnahme angeboten. Zur Verbesserung der Lebensqualität einer Vielzahl von Menschen mit tabakassoziierten Erkrankungen und aus gesundheitsökonomischen Gründen ist es dringend erforderlich, Tabakentwöhnung als flächendeckenden Routineprozess in der medizinischen Versorgung zu etablieren und zu finanzieren.

Significance of Calorie-Restricted Ketogenic Diet for Lung Cancer with Brain Metastases and Hepatoma with Pulmonary Metastases: Two Case Reports

Background: Cancer cells have altered metabolism that is characterized by an enhanced uptake and utilization of glucose. These increased glucose dependence alterations, present potential vulnerabilities that could be targeted for cancer therapy. The calorie-restricted ketogenic diet (KD) may meet the requirement. Case presentation: We present two cases of patients diagnosed with aggressive forms of cancer, lung cancer with brain metastatic tomours and primary liver cancer with pulmonary metastases. The patients began KD intervention after exhausting the other treatment options. Both of them responded to KD and demonstrated a beneficial effect. The tomour size from serial imaging and serum tumour markers were significantly reduced after KD in both subjects without any adverse effects. Both patients had tumour remission even after stopping the ketogenic diet, indicating that KD is a safe, effective treatment for aggressive cancers with metastases when used with conventional therapies. Conclusion: This study demonstrated the significant beneficial effect of a calorie-restricted ketogenic diet for two types of aggressive cancers with metastases. Even a brief KD intervention has a profound effect, implicating the significant therapeutic potential for the ketogenic diet as adjuvant therapy for cancer treatment.

Lentinan triggers oxidative stress-mediated anti-inflammatory responses in lung cancer cells.

Inflammatory responses change several aspects of malignancies such as proliferation, survival, angiogenesis, and metastasis and lead to tumor progression. Lung cancer is the leading type of cancer worldwide and cancer-related inflammatory mediators challenge the successful treatments. Lentinan, a polysaccharide derived from Lentinula edodes, has shown anti-inflammatory characteristics in colitis and has been approved as an adjuvant therapy for cancer treatment. In the present study, we explored the mechanism underlying anti-inflammatory function of Lentinan in lung cancer cells. We showed that Lentinan reduced the inflammatory cytokines IL-6 and IL-1β in LPS-stimulated A549 cells at the concentrations much lower than the IC50. Lentinan failed to alter the NLRP3 expression profile at transcriptional and translational levels. However, it showed a huge inhibition of caspase-1 activity. Lentinan downregulated the expression of IL-6 and IL-1β at the mRNA level. We also showed that Lentinan altered the oxidative status of the cells by increasing the intracellular ROS content and attenuating the activity of GPx4, the key player in the anti-oxidative defense system. Lentinan-induced ROS generation was associated with caspase-3 activation and induction of DNA breaks. This alteration was also associated with mitochondrial membrane depolarization shown by TMRE staining. Using recombinant caspase-1, we showed that Lentinan did not directly target caspase-1 but it led to caspase-1 inhibition. In conclusion, cytotoxicity and anti-inflammatory functions are separated by the dose of Lentinan. Lentinan increased the ROS and mitochondrial dysfunction in a level that is insufficient to induce cell death, but is sufficient to regulate the NLRP3 activation.

Offset-Free Model Predictive Temperature Control for Ultrasound-Based Hyperthermia Cancer Treatments

Heating cancer cells over an extended period of time, referred to as hyperthermia, has been proven to enhance the effects of chemotherapy and radiotherapy without inducing additional toxicity or undesirable side effects, and is therefore considered a highly valuable adjuvant therapy in cancer treatment. In this work, a model predictive control (MPC) setup is developed for improving performance and robustness in regulating the temperature for magnetic-resonance-guided high-intensity focused ultrasound (MR-HIFU) hyperthermia treatments. The proposed control design incorporates a disturbance estimator as encountered in offset-free MPC that is able to remove the steady-state temperature error caused by plant-model mismatch. For the considered healthcare application, such modeling errors are inevitable in practice due to the high variability of tissue properties in patients, some of which even exhibit time- and temperature-dependent behavior due to the body’s thermoregulatory response, combined with the fact that extensive model identification is undesirable in the clinic. The controller’s performance is demonstrated by means of <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</i> experiments on a porcine thigh muscle using a clinical MR-HIFU treatment setup.

From Anti-infective Agents to Cancer Therapy: A Drug Repositioning Study Revealed a New Use for Nitrofuran Derivatives.

The progression of ovarian cancer seems to be related to HDAC1, HDAC3, and HDAC6 activity. A possible strategy for improving therapies for treating ovarian carcinoma, minimizing the preclinical screenings, is the repurposing of already approved pharmaceutical products as inhibitors of these enzymes. This work was aimed to implement a computational strategy for identifying new HDAC inhibitors for ovarian carcinoma treatment among approved drugs. The CHEMBL database was used to construct training, test, and decoys sets for performing and validating HDAC1, HDAC3 and HDAC6 3D-QSAR models obtained by using the FLAP program. Docking and MD simulations were used in combination with the generated models to identify novel potential HDAC inhibitors. Cell viability assays and Western blot analyses were performed on normal and cancer cells for a direct evaluation of the anti-proliferative activity and an in vitro estimation of HDAC inhibition of the compounds selected through in silico screening. The best quantitative prediction was obtained for the HDAC6 3D-QSAR model. The screening of approved drugs highlighted a new potential use as HDAC inhibitors for some compounds, in particular nitrofuran derivatives, usually known for their antibacterial activity and frequently used as antimicrobial adjuvant therapy in cancer treatment. Experimental evaluation of these derivatives highlighted a significant antiproliferative activity against cancer cell lines overexpressing HDAC6, and an increase in acetylated alpha-tubulin levels. Experimental results support the hypothesis of potential direct interaction of nitrofuran derivatives with HDACs. In addition to the possible repurposing of already approved drugs, this work suggests the nitro group as a new zinc-binding group, able to interact with the catalytic zinc ion of HDACs.

Radiosensitizing Effect of Bromelain Using Tumor Mice Model via Ki-67 and PARP-1 Inhibition.

Recent reports have shown that bromelain (BL), a pineapple extract, acts as an adjuvant therapy in cancer treatment and prevention of carcinogenesis. The present study was designed to investigate the possible mechanisms by which BL could radiosensitize tumor cells in vitro and in a mouse tumor model. BL has shown a significant reduction in the viability of the radioresistant human breast carcinoma (MCF-7) cell line using cell proliferation assay. The in vivo study was designed using the Ehrlich model in female albino mice, treated with BL (6 mg/kg b. wt., intraperitoneal, once daily for 10 days) 1 hour before exposure to a fractionated dose of gamma radiation (5 Gy, 1 Gy for 5 subsequent days). The radiosensitizing effect of BL was evident in terms of a significant reduction in tumor volume, poly ADP ribose polymerase-1 (PARP-1), the proliferation marker Ki-67 and nuclear factor kappa activated B cells (NF-κB) with a significant elevation in the reactive oxygen species (ROS) content and lipid peroxidation (LPO) in tumor cells. The present findings offer a novel insight into the radiosensitizing effect of BL and its potential application in the radiotherapy course.

Evaluation of inhibitory effects of geniposide on a tumor model of human breast cancer based on 3D printed Cs/Gel hybrid scaffold

Traditional Chinese medicine therapy, which can serve as adjuvant therapy for cancer treatment, has no obvious side effects on the human body. Geniposide (GEN), one of the main iridoid glycosides in gardenia fruit, has been widely reported to have anti-cancer effects. In this study, we aimed to inspect whether GEN could inhibit proliferation and promote the apoptosis of human breast cancer cells (MCF-7). In order to better predict the efficacy of GEN, we have prepared the Cs/Gel composite scaffolds by 3D printing technology to mimic the MCF-7 cell growth microenvironment. The prepared Cs/Gel scaffold has good mechanical properties and biocompatibility, which can provide a more accurate platform for drug screening. The semi-inhibitory concentration (IC50) evaluated by CCK-8 assay was 16.06 mg/mL (24 h), 14.85 mg/mL (48 h), and 13.14 mg/mL (72 h). After exposed to GEN for 48 h, the cancer cell survival rate reduced from 69.15 ± 2.86% (13 mg/mL) to 20.97 ± 3.24% (16 mg/mL). Although the inhibitory effect was weaker in the 3D culture system, it also managed to inhibit cell proliferation and induce cell apoptosis. Besides, Live/Dead staining, Hematoxylin-Eosin (H&E) staining and SEM evaluation were also conducted to estimate the anti-cancer effect of GEN in 2D and 3D cultures. The results indicate that GEN has an anti-cancer effect based on a time- and dose-dependent manner.

Synergistic Cytotoxic and Apoptotic Effects of Local Probiotic Lactobacillus Brevis Isolated from Regional Dairy Products in Combination with Tamoxifen

Tamoxifen (TAM), the most widely used anti-estrogenic drug, inhibits the progression of breast cancer through competing with estrogen for binding to the estrogen receptor (ER). Tamoxifen has been the first-line adjuvant endocrine therapy in pre- and postmenopausal patients with ER + breast cancer for two decades. However, due to its side effects, interest in using anticancer agents derived from natural foods has increased. It has recently been stated that some probiotics can improve the efficacy of anticancer drugs via synergistic effects. Here, Local Probiotic Lactobacillus Brevis were isolated and characterized from dairy products and its supernatant was prepared. Proliferation of MCF-7, a breast cancer cell line, was investigated after treatment with Lactobacillus Brevis supernatant (LBS) solely, and in combination with Tamoxifen. In Vitro trials were performed to assess the LBS potency. Bax and Bcl-2 mRNA expression levels and apoptotic effects after these treatments were examined by qRT-PCR and flow cytometry, respectively. The results indicated that LBS induces apoptosis in MCF-7 at high concentrations. Transcription of Bcl-2 was reduced but Bax mRNA expression was enhanced. Tamoxifen’s inhibitory effect on the cell growth was synergistically augmented by LBS. In addition, we found that the Bcl-2 mRNA levels in the cells exposed to TAM/LBS were lower than in those treated with TAM alone. Our findings suggest potential role of LB as an adjuvant therapy in cancer treatment and prevention; along with its underlying mechanism

Injectable Drug-Conjugated DNA Hydrogel for Local Chemotherapy to Prevent Tumor Recurrence.

Considering the high rate of postsurgical tumor recurrence due to the possible residual cancer cells and the non-negligible toxicity of postsurgical systemic chemotherapy, we designed an injectable DNA hydrogel assembled by chemodrug-grafted DNA strands for localized chemotherapy. First, a multitude of camptothecin was successfully grafted on backbones of the phosphorothioate DNAs, which could be assembled into two types of Y-shaped building blocks and then hierarchically associated together to form drug-containing hydrogels. The injectable feature of drug-containing DNA hydrogels enables a minimally invasive approach for local drug administration. Owing to the enzymatic degradation, the hydrogel can gradually disassemble into nanosized particles, allowing its good permeation into the residual tumor tissue and efficient uptake by cells. Together with its sustained and responsive drug release behaviors, the drug-containing DNA hydrogel can significantly inhibit the regrowth of tumor cells and prevent cancer recurrence. Compared to the control groups, mice treated with our drug-containing DNA hydrogel show the lowest tumor relapse rate (1/3) and substantial slow tumor progression. Despite the long-term local embedding, negligible systemic toxicity and organ damages are observed after the treatment with our drug-grafted DNA hydrogel. With excellent antitumor efficacy and low side effects in vivo, our DNA-drug conjugate (DDC)-based hydrogel represents a promising candidate for local adjuvant therapy in cancer treatment.

Carboxymethylated Sulfated Heteroexopolysaccharide from a Haloarchaeal Strain as Potential Biomolecule for Harmless Adjuvant Therapy in Cancer Treatment

This study explored the possible use of a microbial carboxymethylated sulfated heteroexopolysaccharide (CS-hEPS) as a potential anticancer agent. The investigation was carried out through antioxidant, antifatigue, and antiproliferative activities. Antioxidant potential including scavenging DPPH and hydroxyl radical activities and reducing power was evaluated. Antifatigue activity was determined by assessing the endurance of mice using the forced swimming test. Following 30 days of CS-hEPS oral treatment at different doses, biochemical parameters related to fatigue such as lactic dehydrogenase (LDH), serum urea nitrogen (SUN), and hepatic glycogen (HG) contents were measured. Antitumor activities were investigated against human cancer liver and myelogenous leukemia cells. Results showed that CS-hEPS possesses notable antioxidant, antifatigue, and antitumor effects. CS-hEPS significantly inhibited the proliferation of leukemia (86.6 ± 0.32%) and cancer liver (58.6 ± 0.43%) cells. CS-hEPS are promising natural antioxidant, antifatigue, and antitumor harmless adjuvant materials that could be applied in human cancer therapy.

Ketogenic Diet as an Adjunctive Therapy on the Treatment of Oral Tumor (P05-020-19)

ObjectivesThis case is here to demonstrate the effectiveness of the Ketogenic Diet (KD) as adjunctive therapy in the treatment of oral fibrosarcoma tumor. MethodsBrad, a five-year-old male mix-breed-dog was submitted on a ketogenic diet after mandibulectomy of the oral tumor. KD a high-fat/low-carbohydrate/adequate-protein diet has recently been proposed as adjuvant therapy in cancer treatment. KDs target the Warburg effect, a biochemical phenomenon in which cancer cells predominantly utilize glycolysis instead of oxidative phosphorylation to produce ATP; therefore, some cancers cannot metabolize ketone bodies, due to mitochondrial dysfunction and down-regulation of enzymes necessary for ketone utilization. Furthermore, by reducing blood glucose, insulin and insulin-like growth factor, the drivers of cancer cell proliferation, are also reduced in the bloodstream. ResultsThis cancer, whose origin is a mesenchymal cell and consists of a malignant tumor of fibroblasts has a reported survival times after surgical excision ranging from 7.0 to 12.2 months. After eighteen months of dietary therapy, the tumor-associated inflammation was completely reduced, and no more lesions were found during clinical exams. The dog in this study showed significant improvement and came back to his normal life and activities right at the beginning of the therapy. Today, he has a healthy happy and very active life. ConclusionsThere are alternatives other than conventional medicine. The therapy plans must include diet either as an adjuvant or whenever possible as the main treatment. Nutrition plays an important role in the future of Medicine. Nontoxic metabolic therapy is effective, and those interested in cancer prevention should know about this. Although the study was managed in a dog, the ketogenic diet is effective in preventing and reducing cancer risks in humans. Integrative Medicine conducted with criteria and responsibility leads to health and vitality for patients. Funding SourcesN/A. Supporting Tables, Images and/or Graphs▪

Miao medicine may serve as an essential adjuvant therapy in cancer treatment

Miao medicine may serve as an essential adjuvant therapy in cancer treatment

A broad-spectrum antibiotic, DCAP, reduces uropathogenic Escherichia coli infection and enhances vorinostat anticancer activity by modulating autophagy

The cellular recycling pathway of autophagy plays a fundamental role in adaptive responses to nutrient deprivation and other forms of stress under physiological and pathological conditions. However, autophagy can also be a double-edge sword during certain bacterial infections (such as urinary tract infections) and in cancer, where it can be hijacked by the pathogens and cancer cells, respectively, to promote their own survival. Thus, autophagy modulation can potentially have multiple effects in multiple contexts and this property can be leveraged to improve outcomes. In this report, we identify that a broad-spectrum antibiotic, 2-((3-(3, 6-dichloro-9H-carbazol-9-yl)-2-hydroxypropyl) amino)-2-(hydroxymethyl) propane-1, 3-diol (DCAP) modulates autophagy. We employed combined biochemical, fluorescence microscopy and correlative light electron microscopy approaches to demonstrate that DCAP treatment blocks autophagy at the late stages by preventing autophagolysosome maturation and interrupting the autophagic flux. We further show that, DCAP significantly reduces UPEC infection in urinary tract epithelial cells via inhibition of autophagy. Finally, we reveal that DCAP enhances the anticancer activity of the histone acetyltransferase (HDAC) inhibitor, vorinostat, which has been reported to increase susceptibility to bacterial infections as a common adverse effect. Collectively, our data support the concept that DCAP represents a valuable chemical scaffold for the development of an innovative class of bactericidal autophagy inhibitors for treatment of urinary tract infections and/or for adjuvant therapy in cancer treatment.

Lanthanide-Doped Core-Shell-Shell Nanocomposite for Dual Photodynamic Therapy and Luminescence Imaging by a Single X-ray Excitation Source.

Photodynamic therapy (PDT) could be highly selective and noninvasive, with low side effects as an adjuvant therapy for cancer treatment. Because excitation sources such as UV and visible lights for most of the photosensitizers do not penetrate deeply enough into biological tissues, PDT is useful only when the lesions are located within 10 mm below the skin. In addition, there is no prior example of theranostics capable of both PDT and imaging with a single deep-penetrating X-ray excitation source. Here we report a new theranostic scintillator nanoparticle (ScNP) composite in a core-shell-shell arrangement, that is, NaLuF4:Gd(35%),Eu(15%)@NaLuF4:Gd(40%)@NaLuF4:Gd(35%),Tb(15%), which is capable of being excited by a single X-ray radiation source to allow potentially deep tissue PDT and optical imaging with a low dark cytotoxicity and effective photocytotoxicity. With the X-ray excitation, the ScNPs can emit visible light at 543 nm (from Tb3+) to stimulate the loaded rose bengal (RB) photosensitizer and cause death of efficient MDA-MB-231 and MCF-7 cancer cells. The ScNPs can also emit light at 614 and 695 nm (from Eu3+) for luminescence imaging. The middle shell in the core-shell-shell ScNPs is unique to separate the Eu3+ in the core and the Tb3+ in the outer shell to prevent resonance quenching between them and to result in good PDT efficiency. Also, it was demonstrated that although the addition of a mesoporous SiO2 layer resulted in the transfer of 82.7% fluorescence resonance energy between Tb3+ and RB, the subsequent conversion of the energy from RB to generate 1O2 was hampered, although the loaded amount of the RB was almost twice that without the mSiO2 layer. A unique method to compare the wt % and mol % compositions calculated by using the morphological transmission electron microscope images and the inductively coupled plasma elemental analysis data of the core, core-shell, and core-shell-shell ScNPs is also introduced.

Asymmetric Assembling of Iron Oxide Nanocubes for Improving Magnetic Hyperthermia Performance.

Magnetic hyperthermia (MH) based on magnetic nanoparticles (MNPs) is a promising adjuvant therapy for cancer treatment. Particle clustering leading to complex magnetic interactions affects the heat generated by MNPs during MH. The heat efficiencies, theoretically predicted, are still poorly understood because of a lack of control of the fabrication of such clusters with defined geometries and thus their functionality. This study aims to correlate the heating efficiency under MH of individually coated iron oxide nanocubes (IONCs) versus soft colloidal nanoclusters made of small groupings of nanocubes arranged in different geometries. The controlled clustering of alkyl-stabilized IONCs is achieved here during the water transfer procedure by tuning the fraction of the amphiphilic copolymer, poly(styrene-co-maleic anhydride) cumene-terminated, to the nanoparticle surface. It is found that increasing the polymer-to-nanoparticle surface ratio leads to the formation of increasingly large nanoclusters with defined geometries. When compared to the individual nanocubes, we show here that controlled grouping of nanoparticles—so-called “dimers” and “trimers” composed of two and three nanocubes, respectively—increases specific absorption rate (SAR) values, while conversely, forming centrosymmetric clusters having more than four nanocubes leads to lower SAR values. Magnetization measurements and Monte Carlo-based simulations support the observed SAR trend and reveal the importance of the dipolar interaction effect and its dependence on the details of the particle arrangements within the different clusters.

Rationale, Feasibility and Acceptability of Ketogenic Diet for Cancer Treatment.

Ketogenic diet has been used for more than 80 years as a successful dietary regimen for epilepsy. Recently, dietary modulation by carbohydrate depletion via ketogenic diet has been suggested as an important therapeutic strategy to selectively kill cancer cells and as adjuvant therapy for cancer treatment. However, some researchers insist ketogenic diet to be highly undesirable as ketogenic diet may trigger and/or exacerbate cachexia development and usually result in significant weight loss. This review revisits the meaning of physiological ketosis in the light of this evidence and considers possibility of the use of ketogenic diet for oncology patients. Article search was performed from 1985 through 2017 and finally 10 articles were analyzed. The review focused on the results of human trials for cancer patients and checked the feasibility of using ketogenic diet for cancer patients as adjuvant therapy. The main outcomes showed improvement of body weight changes, anthropometric changes, serum blood profiles, and reduction in novel marker for tumor progression, TKTL1, and increase of ketone body. Lactate concentration was reduced, and no significant changes were reported in the measurements of quality of life. Ketogenic diet may be efficacious in certain cancer subtypes whose outcomes appear to correlate with metabolic status, but the results are not yet supportive and inconsistent. Therefore, it warrants further studies.